Prelude Capital Management’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $78.2K | Buy |
+25,318
| New | +$78.2K | 0.01% | 929 |
|
|
2023
Q3 | – | Sell |
-18,790
| Closed | -$43.2K | – | 967 |
|
|
2023
Q2 | $43.2K | Sell |
18,790
-12,409
| -40% | -$28.5K | ﹤0.01% | 864 |
|
|
2023
Q1 | $94.5K | Sell |
31,199
-8,950
| -22% | -$27.1K | 0.01% | 860 |
|
|
2022
Q4 | $93.5K | Sell |
40,149
-13,728
| -25% | -$32K | ﹤0.01% | 941 |
|
|
2022
Q3 | $103K | Sell |
53,877
-14,688
| -21% | -$28.1K | ﹤0.01% | 1128 |
|
|
2022
Q2 | $186K | Buy |
68,565
+9,065
| +15% | +$24.6K | 0.01% | 1104 |
|
|
2022
Q1 | $177K | Buy |
59,500
+15,200
| +34% | +$45.2K | 0.01% | 1026 |
|
|
2021
Q4 | $172K | Buy |
44,300
+5,300
| +14% | +$20.6K | ﹤0.01% | 1255 |
|
|
2021
Q3 | $167K | Buy |
+39,000
| New | +$167K | ﹤0.01% | 1063 |
|
|
2021
Q1 | – | Sell |
-45,100
| Closed | -$160K | – | 1070 |
|
|
2020
Q4 | $160K | Buy |
45,100
+100
| +0.2% | +$355 | ﹤0.01% | 693 |
|
|
2020
Q3 | $141K | Buy |
+45,000
| New | +$141K | 0.01% | 587 |
|
|
2017
Q4 | – | Sell |
-3,400
| Closed | -$21K | – | 1176 |
|
|
2017
Q3 | $21K | Buy |
+3,400
| New | +$21K | ﹤0.01% | 1187 |
|
|
2016
Q3 | – | Sell |
-100
| Closed | – | – | 1485 |
|
|
2016
Q2 | $0 | Buy |
+100
| New | – | ﹤0.01% | 1489 |
|
|
2015
Q1 | – | Sell |
-3,000
| Closed | -$46K | – | 1820 |
|
|
2014
Q4 | $46K | Buy |
+3,000
| New | +$46K | 0.01% | 1185 |
|